Biofilms Treatment Market To Reach $6.24 Billion by 2035

Biofilms treatment market is projected to grow from $2.86 billion in 2025 to $6.24 billion by 2035, registering a CAGR of 9.1% during the forecast period (2026–2035). The increasing burden of chronic wounds, hospital-acquired infections, and antimicrobial resistance is significantly accelerating demand for advanced biofilm-targeted therapies worldwide.

Browse the full report description of “Biofilms Treatment Market Size, Share & Trends Analysis Report, By Product Type (Antimicrobial Agents, Debridement Products, Wound Care Dressings, Biofilm Disruption Agents, Advanced Therapies), By Application (Chronic Wounds, Surgical & Traumatic Wounds, Implant-Associated Infections, Respiratory Infections, Urinary Tract Infections), By End-User (Hospitals & Clinics, ASCs, Home Healthcare, Long-Term Care Facilities, Specialty Centers), By Technology (Chemical, Physical, Biological, Nanotechnology, Combination), By Material Type (Silver, Iodine, Polymeric, Hydrocolloids & Hydrogels, Collagen), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/biofilms-treatment-market

A major macro driver for the market is the rising prevalence of healthcare-associated infections (HAIs) and chronic wounds. According to the World Health Organization (WHO), approximately 1 in 10 patients globally is affected by healthcare-associated infections, highlighting the large-scale need for infection control solutions. Additionally, WHO data indicates that over 24% of patients with healthcare-associated sepsis die annually, demonstrating the severity of infection-related complications.

Chronic wounds further amplify this demand. Studies indicate that 1–2% of the population in developed countries suffer from chronic wounds, while diabetic foot ulcers affect a significant share of diabetic patients globally. Moreover, clinical data shows that 50–60% of diabetic foot ulcers become infected, creating a strong requirement for biofilm-targeted antimicrobial therapies. Since biofilms are responsible for persistent infections and delayed healing in most chronic wounds, the need for advanced treatment solutions such as antimicrobial dressings, enzymatic therapies, and biofilm disruption agents continues to rise.

Among product segments, Bio-fungicides (biological anti-biofilm agents) are emerging as the fastest-growing segment. This growth is driven by increasing regulatory restrictions on synthetic antimicrobial agents and a shift toward sustainable and targeted therapies. Biological solutions such as enzyme-based and microbial-derived treatments offer improved efficacy in disrupting biofilm matrices while reducing toxicity and resistance risks.

Recent Developments

• In March 2026, Sanara MedTech reported record revenue of $103.1 million in 2025, driven by strong adoption of its BIASURGE Advanced Surgical Solution, highlighting its effectiveness in preventing and managing biofilms in surgical sites and marking a strategic shift toward biofilm-based infection prevention in operating room settings.
• In January 2025 – Clarametyx Biosciences received funding from CARB-X to advance its anti-biofilm vaccine candidate CMTX-301, designed to disrupt biofilm structures and enhance immune clearance, progressing toward preclinical (IND-enabling) and Phase 1 clinical evaluation.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Type
  • By End Users
  • By Application
  • By Technology
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – Smith+nephew, Convatec Group, molniyke Health care, 3m Health Care, coloplast, among others

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Biofilms Treatment Market Report Segmentation 

 By Product Type

• Antimicrobial Agents
• Debridement Products
• Wound Care Dressings
• Biofilm Disruption Agents
• Advanced Therapies

 By Application

• Chronic Wounds
• Surgical & Traumatic Wounds
• Implant-Associated Infections
• Respiratory Infections
• Urinary Tract Infections (UTIs)

By End-User

• Hospitals & Clinics
• Ambulatory Surgical Centers (ASCs)
• Home Healthcare Settings
• Long-Term Care Facilities (Nursing Homes)
• Specialty Wound Care Centers

 By Technology / Treatment Approach

• Chemical-Based Treatments
• Physical Removal Methods
• Biological Approaches
• Nanotechnology-Based Treatments
• Combination Therapies

 By Material Type

• Silver-Based Materials
• Iodine-Based Materials
• Polymeric Materials
• Hydrocolloids & Hydrogels
• Collagen-Based Materials

Global Biofilms Treatment Market Report Segmentation  by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/biofilms-treatment-market